Abstract: The invention relates to 7H-pyrrolo[2,3-d]pyrimidine derivatives of formula I wherein the symbols and substituents are as defined in the description, to processes for the preparation thereof, to pharmaceutical compositions comprising such derivatives and to the use of such derivatives-alone or in combination with one or more other pharmaceutically active compounds-for the preparation of pharmaceutical compositions for the treatment especially of a proliferative disease, such as a tumour
Type:
Grant
Filed:
August 6, 2002
Date of Patent:
July 17, 2007
Assignee:
Novartis AG
Inventors:
Guido Bold, Hans-Georg Capraro, Giorgio Caravatti, Peter Traxler
Abstract: The invention relates to a new crystalline form of the methanesulfonic acid addition salt of 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide of formula 1, which may be used for example for tumor therapy.
Abstract: The invention provides compounds of formula I or a pharmaceutically acceptable salt or ester thereof (I), wherein the symbols have meaning as defined, which are inhibitors of cathepsin K and find use pharmaceutically for treatment of diseases and medical conditions in which cathepsin K is implicated, e.g.
Type:
Grant
Filed:
August 29, 2002
Date of Patent:
September 26, 2006
Assignee:
Novartis AG
Inventors:
Eva Altmann, Kenji Hayakawa, Genji Iwasaki
Abstract: The invention relates to a new process for concentrating epothilones in culture media, a new process for the production of epothilones, a new process for separating epothilones A and B and a new strain obtained by mutagenesis for the production of epothilones, as well as aspects related thereto. New crystal forms of epothilone B are also described.
Type:
Grant
Filed:
June 12, 2003
Date of Patent:
September 5, 2006
Assignee:
Novartis AG
Inventors:
Hans Hofmann, Marion Mahnke, Klaus Memmert, Frank Petersen, Thomas Schupp, Ernst Kusters, Michael Mutz
Abstract: The invention relates to the treatment of a proliferative disease, especially according to certain treatment regimens, with an epothilone, especially with epothilone A and more preferably epothilone B; as well as to the treatment of certain cancers with such an epothilone.
Type:
Grant
Filed:
March 24, 2005
Date of Patent:
August 15, 2006
Assignee:
Novartis AG
Inventors:
Terence O'Reilly, Markus Wartmann, Manuel Litchman, Pamela Cohen
Abstract: The present invention relates to the use of PDGF receptor tyrosine kinase inhibitors, especially of N-phenyl-2-pyrim-idine-amine derivatives of formula (I), in which the symbols and substituents have the meaning as defined herein in free form or in pharmaceutically acceptable salt form, in the manufacture of a pharmaceutical composition for the treatment of diabetic nephropathy; to a method of treatment of warm-blooded animals, including humans, suffering from diabetic nephropathy; and to the use of a PDGF receptor tyrosine kinase inhibitor of the formula (I), wherein R1 is pyridyl bonded at a carbon atom, R2, R3, R5, R6 and R8 are each hydrogen, R4 is lower alkyl, R7 a radical of formula (II): —N(R9)—C(?X)—(Y)n—R10, wherein R9 hydrogen, X is oxo, n is 0 and R10 is 4-methyl-piperazinyl-methyl, or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for treating glomerulonephritis, chronic pyelonephritis or IgA nephropathy.
Type:
Grant
Filed:
January 3, 2001
Date of Patent:
August 8, 2006
Inventors:
Robert Charles Atkins, Steven James Chadban, Mark Emmanuel Cooper, Richard Ernest Gilbert, Prudence Ann Hill, Darren James Kelly, David John Nikolic-Paterson
Abstract: The invention relates to N-phenyl-2-pyrimidine-amine derivatives of formula (I) wherein the substituents are defined as in the description, to processes for the preparation thereof, to medicaments comprising those compounds, and the use thereof in the preparation of pharmaceutical compositions for the therapeutic treatment of warm-blooded animals, including humans.
Type:
Grant
Filed:
September 11, 2001
Date of Patent:
July 25, 2006
Assignee:
Novartis AG
Inventors:
Hans M Buerger, Giorgio Caravatti, Juerg Zimmermann, Paul W Manley, Werner Breitenstein, Margaret A Cudd
Abstract: The present invention provides new 4-[3,5-bis-(2-hydroxy-phenyl)-[1,2,4]triazol-1-yl]-benzoic acid derivatives which can be used in the treatment of diseases which cause an excess of metal in the human or animal body or are caused by it.
Abstract: A method of treating BCR-ABL positive leukemia in a warm-blooded animal comprising administering the combination of N-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2-pyrimidine-amine, or a pharmaceutically acceptable salt thereof, and telomestatin is disclosed. The combination may optionally have a pharmaceutically acceptable carrier, and the compounds may be administered for simultaneous, separate or sequential use.
Abstract: Epothilone derivatives are co-administered with an antidiarrheal agent, e.g., a DPP-IV inhibitor, in the treatment of a proliferative disease.
Type:
Grant
Filed:
March 18, 2002
Date of Patent:
April 18, 2006
Assignee:
Novartis AG
Inventors:
John David Rothermel, Horst F. Schran, Diane Greeley, TianLing Chen
Abstract: The invention relates to a combination of (a) an inhibitor of platelet-derived growth factor (PDGF) activity and (b) a vector for vascular endothelial growth factor (VEGF-, especially VEGF-C) gene transfer, a pharmaceutical preparation comprising (a) and (b) in combination together with a pharmaceutically acceptable carrier material; a product comprising (a) and (b) as defined above and optionally a pharmaceutically acceptable carrier material, for simultaneous, chronologically staggered or separate use; a method of administering or the use of said combination or product for the treatment of endothelial damage; and/or to the use of (a) and (b) for the manufacture of said pharmaceutical preparation or product for the treatment of endothelial damage.
Type:
Grant
Filed:
August 23, 2002
Date of Patent:
December 13, 2005
Assignees:
Licentia Ltd., Ludwig Institiute for Cancer Research
Inventors:
Kari Alitalo, Carl-Henrik Heldin, Olli Leppänen, Arne Östman, Seppo Ylā-Herttuala
Abstract: 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide of the formula I or a pharmaceutically acceptable salt thereof can be used in the treatment of gastrointestinal stromal tumours.
Type:
Grant
Filed:
October 26, 2001
Date of Patent:
October 25, 2005
Assignees:
Novartis AG, Dana-Farber Cancer Institute, Inc., Oregon Health & Science University
Inventors:
Elisabeth Buchdunger, Renaud Capdeville, George Daniel Demetri, Sasa Dimitrijevic, Brian Jay Druker, Jonathan A. Fletcher, Michael C. Heinrich, Heikki Joensuu, Sandra Leta Silberman, David Tuveson